Journal
RARE DISEASES
Volume 1, Issue 1, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/rdis.27265
Keywords
Mecp2; cholesterol; triglycerides; lipids; autism; mutation; metabolism; statins; HDAC3; fatty liver
Categories
Funding
- Rett Syndrome Research Trust (RSRT)
- International Rett Syndrome Foundation (IRSF) [2608]
Ask authors/readers for more resources
Rett syndrome (RTT), an X-linked neurological disorder caused by mutations in MECP2, may have a metabolic component. We reported a genetic suppressor screen in a Mecp2null mouse model to identify pathways for therapeutic improvement of RTT symptoms. Of note, one suppressor mutation implied that cholesterol homeostasis was perturbed in Mecp2 null mice; indeed, cholesterol synthesis was elevated in the brain and body system. Remarkably, the genetic effect of downregulating the cholesterol pathway could be mimicked chemically by statin drugs, improving motor symptoms, and increasing longevity in the mouse. Our work linked cholesterol metabolism to RTT pathology for the first time. Both neurological and systemic effects of perturbed cholesterol homeostasis overlap with many RTT symptoms. Here we show in patients that peripheral cholesterol, triglycerides, and/or LDLs may be elevated early in RTT disease onset, providing a biomarker for patients that could be aided by therapeutic interventions that modulate lipid metabolism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available